Track topics on Twitter Track topics that are important to you
NEW YORK, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Golden Star Enterprises Ltd. (OTC Pink:GSPT) will launch its consumer drone marketing campaign starting with the upcoming Seattle B2B Gift Show from August 15th to 18th 2015 at the Washington State Convention Centre. With ever increasing public knowledge and curiosity towards these technological gadgets, the drone industry is estimated to expand from its existing $7.8 billion to approximately $13 billion within the next decade, as reported by a recent Business Insiders research report.
Matt Kelly, Director of Golden Star Enterprises Ltd states, "The industry is currently at a stage where drone sale distributions are transitioning from mostly government sales to include consumer purchases as new applications for drones are being used going forward. With the acquisition of NA Drone, we have full capability to manufacture and distribute models that cater to different types of consumers."
Golden Star is expecting positive results from the B2B Gift Show with its NA Drone products' distinct focus on flight quality and user friendly software. The X-factor will stand out as one of the most affordable drones in the market place today while providing image and video quality comparable to competitors' more expensive models. Meanwhile, the Kasper's 1080p motion capturing technology and world-leading "follow me" feature will appeal greatly towards higher-end users.
About Golden Star/NA Drone
Golden Star's North American Drone is a manufacturer and distributor of drones with three different drones in their brand and they are, The X Factor (18.5x18.5x2cm), Kasper (35x35x10cm) and I-Sky (80x40x42cm). NA Drone has an exclusive co-branding, distribution agreement in place with one of the top drone makers in the world to sell co-branded drones throughout North America.
|More information about NA Drone can be found on website www.nadrone.com.|
|For further information contact: 1-888-488-6882|
|/s/ Matt Kelly|
|Matt Kelly, Director|
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical fact are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays in testing and evaluation of products and other risks detailed from time to time in Golden Star's filings with OTC Markets.NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...